Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.48 Increased by +67.57% | -0.53 Increased by +9.43% |
| Aug 8, 23 | -0.92 Increased by +55.77% | -0.68 Decreased by -35.29% |
| Apr 14, 23 | -0.54 Increased by +84.57% | -0.58 Increased by +6.9% |
| Mar 29, 23 | 1.53 Increased by +143.71% | -0.75 Increased by +304% |
| Nov 14, 22 | -1.48 Increased by +63% | -1.75 Increased by +15.43% |
| Aug 11, 22 | -2.08 Increased by +48% | -1.87 Decreased by -11.23% |
| May 13, 22 | -3.5 Increased by +17.65% | -2.37 Decreased by -47.68% |
| Mar 31, 22 | -3.5 Increased by +17.65% | -3.67 Increased by +4.63% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -11.84 M Decreased by -23.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 3.5 M Increased by +250% | -16.65 M Decreased by -133.84% | Decreased by -475.83% Increased by +33.19% |
| Mar 31, 23 | 0 Decreased by -100% | -6.28 M Increased by +70.1% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 68 K Decreased by -97.73% | 6.42 M Increased by +113.74% | Increased by +9.43 K% Increased by +706.25% |
| Sep 30, 22 | 0 Decreased by N/A% | -9.59 M Decreased by -36.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 1 M Increased by +N/A% | -7.12 M Increased by +53.17% | Decreased by -712.2% Decreased by N/A% |
| Mar 31, 22 | 346 K Decreased by -88.47% | -20.99 M Decreased by -31.18% | Decreased by -6.07 K% Decreased by -1.04 K% |
| Dec 31, 21 | 3 M Increased by 0% | -46.68 M Decreased by -194.94% | Decreased by -1.56 K% Decreased by -194.94% |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.